Experimental and investigational therapies for chemotherapy-induced anemia

Bibliography

• Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology 2008;159-65
   PubMedGoogle Scholar
• Macciò A, Madeddu C, Gramignano G, et al. The role of imflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015;100:124-32
   PubMed Web of Science ®Google Scholar
• Wood PA, Hrushesky WJ. Ciaspaltin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95:1650-9
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anemia Survey (ECAS): a large multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:22983-306
   Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer: meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;3:CD007303
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta analysis. CMAJ 2009;180:E62-71
   PubMed Web of Science ®Google Scholar
• Tonia T, Mettler A, Robert N, et al. Erythropoietin and darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407
   PubMed Web of Science ®Google Scholar
• Grant MD, Piper M, Bohluis J, et al. Epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: comparative effectiveness update. Agency for Healthcare Research and Quality 2013; 2013 April Report 13-EHC077-EF
   Google Scholar
• Bohlius J, Tonia T, Nuesch E, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Brit J Cancer 2014;111:33-45
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Browers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De SH, Roila F. Erythropoiesis-stimulating agents in the treatment of anemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-7
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy anaemia: systematic review and meta-analysis of randomized controlled studies. Acta Oncol 2013;52:18-29
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Steensma DP, Auberbach M. Should the ASCO/ASH guidlines for the use of intravenous iron in cancer and chemotherapy-induced anemia be updated. J Natl Compr Cancer Netw 2014;12:657-64
   PubMed Web of Science ®Google Scholar
• Auerbach M. Intravenous iron in chemotherapy-induced anemia. Am J Haematol 2014;89:1153
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sloan JP, Dakhil SR, et al. Phase III, randomized study of the effects of parental iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sasu BJ, Sloan JA, et al. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015;125:3669-71
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open label, randomized controlled study. Oncologist 2010;15:894-902
   PubMed Web of Science ®Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anemia. Support Care Cancer 2014;22:2197-206
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med 2015;21:221-30
   PubMed Web of Science ®Google Scholar
• Kima A, Nemeth E. New insignhts into iron regulation and erythropoiesis. Curr Opin Hematol 2015;22:199-205
   PubMed Web of Science ®Google Scholar
• Pauklin S, Vallier L. Activin/nodal signaling in stem cells. Development 2015;142:607-19
   PubMed Web of Science ®Google Scholar
• Miller KL, Carlino JA, Ogawa Y, et al. Alterations in erythropoiesis in TGF-β 1-treated mice. Exp Hematol 1992;20:951-6
   PubMed Web of Science ®Google Scholar
• Bruno E, Horrigan SK, Van Den Berg D, et al. The Smad5 gene is involved in the intracellular signaling pathways the mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998;91:1917-23
   PubMed Web of Science ®Google Scholar
• Kang YJ, Shin JW, Yoon JH, et al. Inhibition of erythropoiesis by Smad6 in human cord blood hematopoietic stem cells. Biochem Biophys Res Commun 2011;423:750-6
   Web of Science ®Google Scholar
• Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011;117:4915-23
   PubMed Web of Science ®Google Scholar
• Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008;112:3434-43
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003;282:110-20
   PubMed Web of Science ®Google Scholar
• Shiozaki M, Sakai R, Tabuchi M, et al. In vivo treatments with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (BFU-E and CFU-E) in mice. Biochem Biophys Res Commun 1989;165:1155-61
   PubMed Web of Science ®Google Scholar
• Fuchs O, Simakova O, Klener P, et al. Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4. Blood Cells Mol Dis 2002;28:221-33
   PubMed Web of Science ®Google Scholar
• Perry JM, Harandi OF, Paulson RF. BMP4, SCF and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors. Blood 2007;109:4494-502
   PubMed Web of Science ®Google Scholar
• Perry JM, Harandi OF, Porayette P, et al. Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling. Blood 2009;113:911-18
   PubMed Web of Science ®Google Scholar
• Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12:586-97
   PubMed Web of Science ®Google Scholar
• Fields SZ, Parshad S, Anne M, et al. Activin receptor agonists for cancer-related anemia and bone disease. Expert Opin Invest Drugs 2013;22:87-101
   PubMed Web of Science ®Google Scholar
• Mulivor A, Barbosa D, Kumar R, et al. RAP-011, a soluble activin receptor type IIa murine IgG-Fc fusion protein, prevents chemotherapy induced anemia. Blood 2009;114:Abstract 161
   Google Scholar
• Iancu-Rubin C, Mosogan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 2013;41:155-66
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and hemoglobin. Brit J Haematol 2014;165:870-82
   PubMed Web of Science ®Google Scholar
• Yamawaki K, Ueda S, Okada T, et al. Adult-specific systemic overexpression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. PLoS ONE 2013;8:e78076
   PubMed Web of Science ®Google Scholar
• Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nature Med 2014;20:398-407
   PubMed Web of Science ®Google Scholar
• Langdon JM, Barkataki S, Berger AE, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Haematol 2015;90:8-14
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausam women. J Bone Miner Res 2009;24:744-52
   PubMed Web of Science ®Google Scholar
• Sherman ML, Borgstein NG, Mook L, et al. Multiple dose, safety, pharmacokinetic, and pharmacodynamics study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent in healthy postmenopausal women. J Clin Pharmacol 2013;53:1121-30
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov K, Salogub G, Khuazheva N, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Brit J Haematol 2014;165:814-23
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, Origa R, et al. A phase 2a, open label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta(β)-thalassemia: interim results. Blood 2013;Abstract 3448
   Google Scholar
• Komrokji R, Garcia-Manero G, Ades L, et al. An open-label, phase-2, dose-finding study of Sotatercept (ACE-011) in patients with low or intermediate-1 (Int-1)-risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. ASH Meeting 2014;Abstract 3251
   Google Scholar
• Suragani R, Cadena S, Cawley S, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014;20:408-14
   PubMed Web of Science ®Google Scholar
• Suragani R, Cawley S, Li R, et al. Modified activin receptor IIb ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood 2014;123:3864-72
   PubMed Web of Science ®Google Scholar
• Attie KM, Allison MJ, McClure T, et al. A phase I study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Haematol 2014;89:766-70
   PubMed Web of Science ®Google Scholar
• Piga A, Perrotta S, Melpignano A, et al. ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassemias: preliminary results from a phase 2 study. ASH Meeting 2014;Abstract 53
   Google Scholar
• Platzbecker U, Germing U, Giagounidis A, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate 1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. ASH Meeting 2014;Abstract 411
   Google Scholar
• Theurl I, Schroll A, Sonnweber T, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011;118:4977-84
   PubMed Web of Science ®Google Scholar
• Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76
   PubMed Web of Science ®Google Scholar
• Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115:3616-24
   PubMed Web of Science ®Google Scholar
• Cooke KS, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013;22:3054-61
   Web of Science ®Google Scholar
• Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics. Drug Discov Today 2015;20:147-55
   PubMed Web of Science ®Google Scholar
• Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomoglus monkeys. Blood 2013;121:2311-15
   PubMed Web of Science ®Google Scholar
• Van Eijk LT, John AS, Schoebel F, et al. Effect of the anti-hepcidin Spigelmer lexapeptid on inflammation-induced decrease in serum iron in humans. Blood 2014;124:2643-6
   PubMed Web of Science ®Google Scholar
• Georgiev P, Lazarolu M, Ocroteala L, et al. The anti-hepcidin Spiegelmer Lexapeptid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma and CLL: a phase II pilot study. AACR Meeting 2014;Abstract 3847
   Google Scholar
• Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as erythroid regulator of iron metabolism. Nat Genet 2014;46:678-84
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery fron anemia of inflammation. Blood 2014;124:2569-74
   PubMed Web of Science ®Google Scholar
• Forristal CE, Levesque JP. Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cell Transl Med 2014;3:135-40
   PubMed Web of Science ®Google Scholar
• Hollingworth K, Romney MC, Crawford A, et al. Risk evaluation mitigation strategy: impact of application of the Food and Drug Administration’s strategy of erythropoiesis-stimulating agents and transfusions in patients with chemotherapy-induced anemia. J Clin Pharmacol Ther 2015;40:299-303
   PubMed Web of Science ®Google Scholar